Skip to main navigation Skip to main content Skip to page footer
Menu

MUSCLE DISEASES - CLINIC

OUTPATIENT CLINIC FOR ACQUIRED AND HEREDITARY MUSCLE DISEASES-TRAINING - EDUCATION AND RESEARCH

 

The outpatient clinic for acquired and hereditary muscle diseases is a hub for clinical and research excellence across the spectrum of neuromuscular diseases in Greece

 

Training/Education activities:

  • Our outpatient clinic participates in the supervision and training of Neurology residents of the 1st Department of Neurology. Moreover, we participate in the clinical grand rounds of the Department with presentations of unique and interesting cases.
  • We participate in seminars, courses and workshops held by the 1st Department of Neurology in order to train and educate young Neurologists in the field of neuromuscular diseases.

 

Research activities:

  • Study of muscle specific miRNAs in serum of patients with acquired and hereditary muscle diseases
  • Genetic characterization of rare myofibrillar myopathies followed in our outpatient
  • Genetic characterization and study of disease mechanisms in rare hereditary myopathies
  • Natural history study of myotonic dystrophy type 2
  • Central nervous system involvement in patients with myotonic dystrophy type 2
  • Natural history in various hereditary and in acquired inflammatory myopathies
  • Study of effect of exercise training on functional capacity of
  • Natural history study of Spinal Muscular Dystrophy patients

 

Recent publications

  1. Papadopoulos C, Kekou K, Xirou S,Kitsiou-TzeliS, Kararizou E, PapadimasGK. Early-onset posterior subscapular cataract in a series of myotonic dystrophy type 2 patients. Eye (Lond). 2018 Mar;32(3):622-625
  2. Papadimas GΚ, Paraskevas GP, Zambelis T, Karagiaouris C, Bourbouli M, Bougea A, Walter MC, Schumacher NU, Krause S, Kapaki E. The multifaceted clinical presentation of VCP-proteinopathy in a Greek family. ActaMyologica. 2017; [Epub ahead of print].
  3. Zachou A, Zouvelou V, Papadimas GK,  Rentzos M, Papadopoulos C.  Anti-TIF1-γ autoantibodies–positive dermatomyositis: where is the malignancy? Rheumatology (Oxford). 2017 Aug 30
  4. Koutsoulidou A, Photiades M, Kyriakides TC, Georgiou K, Prokopi M, Kapnisis K, Lusakowska A, Nearchou M, Christou Y, Papadimas GK, Anayiotos A, Kyriakou K, Kararizou E, Zamba-Papanicolaou E, Phylactou LA. Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress. Hum Mol Genet. 2017 Sep 1;26(17):3285-3302.
  5. Papadimas GK, Evila A, Paoadopoulos C, Kararizou E, Manta P, Udd B. GNE-myopathy in a Greek romani family with unusual calf phenotype and protein aggregation.  J.Neuromuscul.Dis. 2016; 3(2):283-288
  6. Koutsoulidou A, Kyriakides TC, Papadimas GK, Christou Y, Kararizou E, Papanicolaou EZ, Phylactou LA. Elevated muscle-specific miRNAs in serum of myotonic dystrophy patients relate to muscle disease progress. PLoSOne. 2015 Apr 27;10(4):e0125341
  7. Papadopoulos C, Papadimas GK, Kekou K, Spengos K, Kitsiou-Tzeli S, Manta P. Caveolinopathies in Greece. The Neurologist 2015;20(1):8-12.
  8. Papadimas GK, Kekou K, Papadopoulos C, Kararizou E, Kanavakis E, Manta P. Phenotypic variability and molecular genetics in proximal myotonic myopathy. Muscle Nerve 2015;51(5):686-91
  9. Papadopoulos C, Papadimas GK, Michelekakis H, Manta P. Highlighting intrafamiliar clinical variability in late-onset Pompe disease. Mol Genet Metab Reports 2014;1:2-4
  10. Papadimas G, Terzis G, Papadopoulos C, Areovimata A, Spengos K, Kavouras S, Manta P. Bone density in patients with late onset Pompe disease. Int J EndocrinolMetab 2012;10(4):599-603.
  11. Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab 2012;107(4):669-73
  12. Papadopoulos C, Papadimas GK, Spengos K, Manta P. Pretreatment antibodies against acis α-glycosidase in a patient with late-onset disease. Muscle Nerve 2012;45(3):452
  13. Papadimas GK, Spengos K, Papadopoulos C, Manta P. Late-onset glycogen storage disease type II: pitfalls in the diagnosis. EurNeurol 2012;67(2):65-8.
  14. Terzis G, Dimopoulos F, Papadimas GK, Papadopoulos C, Spengos K, Fatouros I, Kavouras SA, Manta P. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy.MolGenetMetab 2011;104(3):279-83
  15. Papadopoulos C, Papadimas GK., Spengos K., Manta P. Bent spine syndrome in facioscapulohumeral muscular dystrophy. MuscleNerve 2011;43(4):615
  16. Papadimas GK, Spengos K, Konstantinopoulou A, Vassilopoulou S,  Vontzalidis A,  Papadopoulos C, Michelakakis H, Manta P. Adult Pompe disease: ClinicalmanifestationsandoutcomeofthefirstGreekpatientsreceivingenzymereplacementtherapy. ClinNeurol Neurosurg2011;113(4):303-7
  17. Papadimas GK, Terzis G, Methenitis S, Spengos K, Papadopoulos C, Vassilopoulou S, Kavouras S, Michelakakis H, Manta P. Body composition analysis in late-onset Pompe disease. MolGenetMetab 2011;102(1):41-3
  18. Papadimas GK, Terzis G, Spengos K, Methenitis S, Papadopoulos C, Vassilopoulou S, MantaP. BonemineraldensityinadultpatientswithPompedisease. Bone 2011;48(2):417
  19. Papadimas GK, Terzis G, Papadopoulos C, Spengos K, Manta P. The importance of nutritional status in the prognosis of late onset Pompe disease. Mol Genet Metab 2010;100: 389

1ST DEPARTMENT OF NEUROLOGY: